The clinical value of plasma trimethylamine-N-oxide and its metabolites in predicting recurrent atrial fibrillation after catheter ablation

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100042262

Enrollment

Unknown

Registered

2021-01-17

Start date

2021-02-01

Completion date

Unknown

Last updated

2021-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

paroxysmal atrial fibrillation group vs persistent atrial fibrillation group:Nil

recurrence group vs non recurrence group:Nil

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Atrial fibrillation meet the indication of catheter ablation in 2020 ESC Guidelines.

Exclusion criteria

Exclusion criteria: (1) patients with prior AF ablation attempts; (2) Left atrial thrombosis; (3) Anticoagulant contraindications; (4) Failure to ablation; (5) Reject the research.

Design outcomes

Primary

Measure	Time frame
recurrent atrial fibrillation;	—

Countries

China

Contacts

Public ContactLing Yang

Changzhou First People's Hospital (The Third Affiliated Hospital of Soochow University)

linda_yl@sina.com+86 13616110633

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026